SEC FORM 4

Please wait

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Barchas Isaac

(Last)

(First)

(Middle)

C/O IMMUNOME, INC.

18702 N. CREEK PARKWAY, SUITE 100

(Street)

BOTHELL

98011

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Immunome Inc. [ IMNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/30/2026		S⁽¹⁾		101,050⁽²⁾	D	$21.12⁽³⁾	308,504	I	See footnotes⁽⁴⁾⁽⁵⁾
Common Stock	07/02/2026		S⁽¹⁾		75,665	D	$22.35⁽⁶⁾	232,839	I	See footnote⁽⁷⁾
Common Stock	07/02/2026		S⁽¹⁾		24,335	D	$23.33⁽⁸⁾	208,504	I	See footnote⁽⁷⁾
Common Stock								103,259⁽⁹⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The reported sale of these shares occurred automatically pursuant to Rule 10b5-1 trading plans adopted by ABHMC II LLC ("ABHMC") and Arsenal Bridge Venture II-B LLC ("ABV II-B"), each on March 31, 2026.

2. The shares were sold as follows: 100,000 shares were sold by ABHMC and 1,050 shares were sold ABV II-B.

3. The weighted average sale price for the transaction report was $21.12, and the range of prices were between $20.83 and $21.47, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

4. The shares of Issuer common stock held by the Reporting Person prior to the transaction reported herein reflect pro rata distributions in kind for no additional consideration, effected by each of Arsenal Bridge Venture II LLC ("ABV II") and ABV II-B to their respective members, including ABHMC, the managing member of ABV II and ABV II-B. The receipt of such shares by the Reporting Person constituted a change in form of ownership and, therefore, was not required to be reported pursuant to Section 16, including Rule 16a-13. Following this transaction, ABHMC owns the remaining 308,504 shares of Issuer common stock.

5. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC and is a co-founder and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABV II-B. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.

6. The weighted average sale price for the transaction report was $22.35, and the range of prices were between $22.015 and $23.015, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

7. ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.

8. The weighted average sale price for the transaction report was $23.33, and the range of prices were between $23.03 and $23.67, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

9. The shares of Issuer common stock held by the Reporting Person prior to the transaction reported herein reflect pro rata distributions in kind for no additional consideration, effected by ABV II to its members of the shares received in such distributions by members, including the Reporting Person. The receipt of such shares by the Reporting Person constituted a change in form of ownership and, therefore, was not required to be reported pursuant to Section 16, including Rule 16a-13.

	/s/ Sandra Stoneman, Attorney-in-Fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.